US progress for Refractec's presbyopia CK (Conductive Keratoplasty) trial
This article was originally published in Clinica
Executive Summary
Refractec looks on track to submit a US marketing application for its Conductive Keratoplasty (CK) treatment for presbyopia, after completing the patient enrolment phase of an FDA-phase III clinical trial of the technique.